24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
NAVELIEVA 50MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | NAVELIEVA 50MG |
|---|---|
| Composition | Vinorelbine Injection IP 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
NAVELIEVA 50MG (Vinorelbine Injection IP 50mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
NAVELIEVA 50 MG (Vinorelbine Injection IP 50 mg) is a prescription anticancer medicine used for the treatment of various cancers, particularly Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer. It contains Vinorelbine 50 mg, a chemotherapy agent belonging to the class of medicines known as Vinca Alkaloids. The medicine works by disrupting the division and growth of cancer cells, helping to slow disease progression and reduce tumor burden.
Cancer develops when abnormal cells multiply uncontrollably and spread throughout the body. For cancer cells to divide and grow, they rely on specialized structures called microtubules. Vinorelbine interferes with the formation and function of these microtubules, preventing cancer cells from completing the cell division process. As a result, the affected cells stop growing and eventually die.
NAVELIEVA 50 MG is widely used in oncology treatment programs and is often prescribed either as a single-agent therapy or in combination with other anticancer medicines. Its proven effectiveness has made it an important component of modern chemotherapy protocols for several solid tumors.
The medicine is commonly recommended for:
Vinorelbine may be used when cancer has spread beyond its original location or when additional treatment options are required after previous therapies. Treatment decisions are made based on cancer type, stage, overall patient health, and therapeutic goals.
Manufactured under strict pharmaceutical quality standards, NAVELIEVA 50 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals in hospitals, oncology centers, and specialized cancer treatment facilities.
Patients receiving Vinorelbine therapy often require regular blood tests, liver function assessments, and routine medical monitoring to evaluate treatment response and manage potential side effects effectively.
Due to its established clinical effectiveness and role in cancer management, NAVELIEVA 50 MG remains a valuable treatment option in modern oncology care.
NAVELIEVA 50 MG (Vinorelbine Injection IP 50 mg) is primarily used for the treatment and management of specific cancers.
The medicine is widely used in the treatment of advanced and metastatic non-small cell lung cancer.
Doctors may prescribe Vinorelbine for patients with advanced breast cancer that has spread beyond the breast tissue.
The medicine helps manage breast cancer that has spread to other parts of the body.
Vinorelbine is frequently used with other anticancer medicines to improve treatment outcomes.
The medicine may be prescribed when cancer returns after previous therapy.
NAVELIEVA may be included in selected oncology treatment protocols for advanced solid tumors.
Vinorelbine belongs to a class of medicines known as Vinca Alkaloids.
NAVELIEVA works by:
This mechanism helps control disease progression and improve cancer management outcomes.
Like all chemotherapy medicines, NAVELIEVA 50 MG may cause side effects in some patients. Side effects vary depending on treatment duration, dosage, and individual patient response.
Weakness and tiredness are frequently reported during treatment.
Patients may experience mild to moderate nausea.
Episodes of vomiting may occur in some individuals.
Constipation is one of the commonly reported digestive side effects.
Reduced appetite may affect nutritional intake.
Temporary hair thinning or hair loss may occur during therapy.
Pain, redness, or irritation at the injection site may develop.
Some patients may experience body aches and discomfort.
Vinorelbine may reduce:
This may increase the risk of infection, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of NAVELIEVA 50 MG (Vinorelbine Injection IP 50 mg) should always be determined by a qualified oncologist or healthcare professional.
Different cancers may require different treatment protocols.
Dosage is commonly calculated according to body size.
Treatment decisions often depend on laboratory test results.
Patients with liver impairment may require dosage adjustments.
Doctors may modify treatment based on effectiveness and side effect management.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of non-small cell lung cancer and advanced breast cancer.
Vinorelbine is a chemotherapy medicine that belongs to the Vinca Alkaloid class and works by preventing cancer cell division.
Yes, it is a chemotherapy medicine used in various oncology treatment protocols.
Yes, it is often included in combination chemotherapy regimens.
Yes, Vinorelbine may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Yes, doctors typically recommend blood tests, liver function assessments, and routine medical evaluations throughout therapy.
No, chemotherapy treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.